Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 2/20 | 0.52 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.50 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.50 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.50 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567601 | 1.00 | PDPK1 (0.59) | PDPK1FFAR1ACLYGPR17HPGD | |
| SCHEMBL4778926 | 0.91 | ACLY (0.58) | PDPK1FFAR1ACLYPLAAT3PLAAT5 | |
| Hydrochloric Acid SCHEMBL9083841 | 0.89 | ACLY (0.57) | PDPK1FFAR1ACLYPLAAT3PLAAT5 | |
| SCHEMBL6207183 | 0.87 | ACLY (0.63) | ACLY | |
| SCHEMBL7330078 | 0.86 | PDPK1 (0.56) | PDPK1ACLYHPGDCNR1PLAAT3 | |
| SCHEMBL10276916 | 0.86 | ACLY (0.65) | ACLY | |
| SCHEMBL32689799 | 0.85 | FFAR1 (0.49) | PDPK1FFAR1GPR17ALDH1A1 | |
| SCHEMBL4699761 | 0.85 | FFAR1 (0.49) | PDPK1FFAR1GPR17ALDH1A1 | |
| SCHEMBL2489075 | 0.85 | PDPK1 (0.55) | PDPK1ACLYHPGDCNR1PLAAT3 | |
| SCHEMBL14793675 | 0.83 | POLB (0.50) | PDPK1FFAR1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| WO-2023160582-A1 | THIAZOLAMINE MBL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-115160285-A | Thioamides ALDH 2 Agonist, preparation method and application | 云南大学 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022178544-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE IN HDAC INHIBITION | KLOTHO THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | disclosed |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2935249-B1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-5453424-A | Furanodiazepines | MERCK & CO., INC. (US) | 1995-09-26 | — | — | US | disclosed |
| US-5428031-A | Benzodiazepine analogs; cardiovascular disorders | MERCK & CO., INC. (US) | 1995-06-27 | — | — | US | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014694-A1 | BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014695-A1 | NOVEL FURANODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014470-A1 | METHODS OF TREATING CARDIAC ARRHYTHMIA | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1995014671-A1 | 3-ACYLAMINOBENZAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1994026692-A1 | BICYCLIC AMIDE DERIVATIVES AND THEIR USE AS MUSCLE RELAXANTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-11-24 | — | — | WO | disclosed |
| US-3975429-A | Cyclopropanemethyl esters of cinnamic acid and derivatives thereof | ZOECON CORPORATION (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | PDPK1 3592/4885FFAR1 713/4885ACLY 1917/4885 |
| US-10456472-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | PDPK1 3592/4885FFAR1 713/4885ACLY 1917/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | PDPK1 3592/4885FFAR1 713/4885ACLY 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.